中国实用内科杂志2018，Vol.38Issue(4)：364-369,6.DOI:10.19538/j.nk2018040114
先天性心脏病相关性肺动脉高压患者血清高迁移率组蛋白B1变化及其临床意义
Serum high mobility group box 1 levels and its clinical significance in patients with pulmonary arterial hypertension associated with congenital heart disease.
摘要
Abstract
Objective To estimate the clinical value of serum high mobility group box 1(HMGB1) as a biomarker of pulmonary arterial hypertension with congenital heart disease (CHD-PAH). Methods This study included 83 patients with pulmonary arterial hypertension associated with congenital heart disease in the Second Xiangya Hospital, Central South University from May 2013 to April 2015, and all the patients are divided into two groups according to mean pulmonary artery pressure(MPAP): congenital heart disease with mild-to-moderate pulmonary arterial hypertension group(group A1, n=23) and congenital heart disease with severe pulmonary arterial hypertension group(group A2, n=60). Then set two control groups: congenital heart disease without pulmonary arterial hypertension group(group B, n=23) and healthy adult control group(group C, n=20). Of all the patients with CHD-PAH, 18 were followed up for 6 months during treating with PAH-specific pharmacotherapies. All the subjects' clinical data were collected, cardiac catheterization and echocardiographs were performed. HMGB1 levels were determined by enzyme linked immunosorbent assay(ELISA). Results Serum HMGB1 levels were significantly increased in patients with CHD-PAH compared with CHD without PAH and control group(16.19±7.67 μg/L vs. 5.35±2.03 μg/L, 16.19±7.67 μg/L vs. 3.76±1.25 μg/L; P<0.05); Serum HMGB1 levels were significantly increased in patients with mild-to-moderate CHD-PAH group compared with severe CHD-PAH group(19.12±6.70 μg/L vs. 8.54±3.71 μg/L, P<0.05). The serum HMGB1 levels were significantly positive correlation with MPAP(r=0.864, P<0.05) in patients with CHD. After treating with PAH-specific pharmacotherapies for 6 month, HMGB1 levels were significantly decreased(18.12±5.31 μg/L vs. 13.51±1.47 μg/L, P<0.05) along with the patients' MPAP(65.1±10.1mmHg vs. 55.3±9.2 mmHg, P<0.05) and six minutes walk distances improved. Conclution Our study suggested that serum HMGB1 may be used as a biomarker to identify CHD-PAH, to assess the pulmonary vascular remodeling in patients with PAH. Furthermore, HMGB1 level was a marker of treatment response to targeted therapy so that it has the potential to be used as a biomarker in the follow-up evaluation of patients with CHD-PAH.关键词
肺动脉高压/先天性心脏病/高迁移率族蛋白B1/艾森曼格综合征/肺动脉高压靶向药物.Key words
pulmonary arterial hypertension/congenital heart disease/high mobility group box 1/eisenmenger's syndrome/PAH-specific pharmacotherapies分类
医药卫生引用本文复制引用
罗俊,苏威,朱腾腾,王懿,盛斌,熊贤良,李江..先天性心脏病相关性肺动脉高压患者血清高迁移率组蛋白B1变化及其临床意义[J].中国实用内科杂志,2018,38(4):364-369,6.基金项目
国家自然科学基金面上项目(81370249) （81370249）
国家自然科学基金青年基金(81600249) （81600249）
湖南省自然科学基金青年基金(2017JJ3455) （2017JJ3455）
